Apollo Neuroscience Inc.

Apollo Neuroscience Inc. develops innovative wearable technology designed to enhance well-being by managing stress, improving sleep quality, and boosting performance through scientifically-backed solutions. Founded in 2016 and headquartered in Pittsburgh, US, Apollo Neuroscience Inc. specializes in creating wearable devices that help users control anxiety and improve their overall wellness.

The founders, David Rabin and Kathryn Fantauzzi, have backgrounds in neuroscience and technology. In September 2021, the company raised USD 8. 000 mn in a Series A funding round led by Noetic Fund, totaling USD 8. 000 mn raised to date and currently valued at USD 100.

000 mn. Apollo Neuroscience focuses on the development of wearable devices that enhance well-being by addressing stress, sleep quality, and overall performance. Their flagship product, the Apollo wearable, uses gentle vibrations known as Apollo Vibes™ to help users manage anxiety, improve focus, and promote better sleep without pharmaceuticals. The device is aimed at individuals seeking wellness improvements and is marketed through a direct-to-consumer model, with sales concentrated in North America and select international markets.

Apollo Neuroscience generates revenue primarily from direct consumer sales of its Apollo wearable device, available for purchase on its official website. The company may also offer subscription services for app features that enhance the user experience. This transactional model caters to a wide audience, ensuring ongoing revenue from users committed to their wellness journey through the product and associated services. In September 2021, Apollo Neuroscience Inc.

secured USD 8. 000 mn in Series A funding, which will be directed towards reaching new global users. The company plans to expand its product offerings and enter new markets, although specific products and markets have not been detailed. The recent funding is expected to support these strategic initiatives and enhance their overall market presence.